Tim Schroeder

Dr. Tim Schroeder

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DSDavid Steindl
David Steindl
TSTim Schroeder
Tim Schroeder
AKAlexander Krannich
Alexander Krannich
JNJens Nee
Jens Nee
Background/Objectives: Septic shock remains a significant clinical challenge with consistently high mortality rates. Recent investigations have focused on the efficacy of CytoSorb® (CytoSorbents Corporation, Monmouth Junction, NJ, USA), an extracorporeal cytokine adsorber, and how it impacts outcomes in sepsis. The current meta-analysis reports on the impact of CytoSorb® on survival, specifically in septic shock patients. Methods: We conducted a comprehensive systematic search across the PubMed and COCHRANE databases for studies published up to 10 June 2024. The analysis prioritized randomized controlled trials and observational studies with control groups involving septic shock patients while excluding case reports and case series. Nine studies were finally included in our meta-analysis following the initial screening of 115 articles after excluding duplicates and irrelevant entries. Results: The meta-analysis was performed on 744 critically ill patients with septic shock from one RCT and eight observational studies. Of these, 449 patients received treatment with CytoSorb® in addition to standard care. Our data indicate that CytoSorb® use is associated with reduced in-hospital mortality, evidenced by an odds ratio (OR) of 0.64 [0.42; 0.97] and a p-value of 0.036. For 28–30-day mortality, the findings were more pronounced with an OR of 0.46 [0.28; 0.78] and a p-value of 0.003. The analysis of the longest observed mortality showed a trend for improved survival within the CytoSorb group; however, it did not reach statistical significance. Additionally, there was a significant improvement in hemodynamic stability as a secondary endpoint, as evidenced by notable reductions in vasopressor requirements in the hemoadsorption group. Conclusions: The current meta-analysis suggests that the use of CytoSorb® alongside standard of care management may be linked to improved short-term survival in patients with septic shock; however, these findings should be interpreted with caution in light of the heterogeneity and the modest quality of the studies included. Prospective studies are needed to better determine the impact of hemoadsorption on shock reversal and survival in these critically ill patients.

1 October 2021 in Journal of Critical Care
Verified
Journal Article
Closed access
TSTim Schroeder
Tim Schroeder
JKJan Matthias Kruse
Jan Matthias Kruse
FMFlorian Marcy
Florian Marcy
SPSophie K. Piper
Sophie K. Piper
CSChristian Storm
Christian Storm
JNJens Nee
Jens Nee

16 January 2025 in Trends in Anaesthesia and Critical Care
Verified
Journal Article
Open access
TSTim Schroeder
Tim Schroeder
JNJens Nee
Jens Nee
SKSarah Kamel
Sarah Kamel
CSChristian Storm
Christian Storm
CHCarl Hinrichs
Carl Hinrichs
BSBettina Schueler
Bettina Schueler

24 February 2023 in Trends in Anaesthesia and Critical Care
Verified
Journal Article
Closed access
TSTim Schroeder
Tim Schroeder
JKJan Matthias Kruse
Jan Matthias Kruse
SPSophie K. Piper
Sophie K. Piper
KGKatharina Goettfried
Katharina Goettfried
SKStoyan Karaivanov
Stoyan Karaivanov
FMFlorian Marcy
Florian Marcy